In Brief This Week: Roche; Danaher; Transgenomic; and More | GenomeWeb

NEW YORK (GenomeWeb) — Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week. Wilmington, Massachusetts-based Kapa develops genomics tools. Its acquisition will add to Roche's NGS portfolio by building on its existing NGS target enrichment products, Roche said. Terms of the deal were undisclosed.


Danaher announced this week that its board of directors has approved a quarterly share dividend of $.135 per share, which will be paid on Jan. 29, 2016 to holders of record on Dec. 21, 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.